Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 5
Submit an article Journal homepage
2,452
Views
2
CrossRef citations to date
0
Altmetric
Coronavirus – Letters

COVID-19 vaccine associated transverse myelitis-Evusheld as an option when vaccination is not recommended due to severe adverse events

William E. FitzsimmonsDepartment of Pharmacy Systems, Outcomes and Policy, University of Illinois College of Pharmacy, Chicago, IL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6189-5499View further author information
ORCID Icon
Article: 2068338 | Received 04 Apr 2022, Accepted 15 Apr 2022, Published online: 05 May 2022

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Andrew Ustianowski. (2022) Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review. Expert Review of Anti-infective Therapy 20:12, pages 1517-1527.
Read now

Articles from other publishers (1)

Mohammed Kamal Nassar, Alaa Sabry, Mohamed Elgamal, Zeinab Zeid, Dalia Abdellateif Abdelghany & Samar Tharwat. (2023) Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study. Medicina 59:12, pages 2109.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.